FDA to give Salix IBS drug priority review

08/11/2010 | American City Business Journals

The FDA said it would give priority review to Xifaxan, from Salix Pharmaceuticals, as a treatment for irritable bowel syndrome. The drug already is approved for traveler's diarrhea and hepatic encephalopathy, and Phase III clinical trials showed it lessens the abdominal pain and bloating of IBS.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI